Media Articles Related to Vaprisol (Conivaptan)
Source: MedicineNet Pendred Syndrome Specialty [2016.07.28]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/28/2016 12:00:00 AM
Hypothyroidism During Pregnancy
Source: MedicineNet levothyroxine sodium Specialty [2016.02.03]
Title: Hypothyroidism During Pregnancy
Category: Diseases and Conditions
Created: 11/30/1999 12:00:00 AM
Last Editorial Review: 2/3/2016 12:00:00 AM
Published Studies Related to Vaprisol (Conivaptan)
Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. [2011.06]
BACKGROUND: Conivaptan is an arginine-vasopressin-receptor antagonist approved for the treatment of hyponatremia. We hypothesized that administration of conivaptan to normonatremic patients with traumatic brain injury (TBI) is safe and could reduce intracranial pressure (ICP)... CONCLUSIONS: These data suggest that a single dose conivaptan is safe in non-hyponatremic patients with severe TBI and may reduce ICP. Further studies are needed to establish the effect of conivaptan on clinically relevant endpoints, and its role in the management of intracranial hypertension.
Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. [2011.05.01]
PURPOSE: The efficacy and safety of conivaptan administered via 30-minute i.v. infusion to patients with euvolemic or hypervolemic hyponatremia were evaluated... CONCLUSION: Conivaptan hydrochloride 20 mg, administered once or twice daily via 30-minute i.v. infusion, significantly increased SSCs over 48 hours in patients with euvolemic or hypervolemic hyponatremia when compared with placebo. Common AEs were similar to those seen with continuous conivaptan infusions.
Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia. [2009.01]
BACKGROUND:: In most cases of hyponatremia, arginine vasopressin secretion is inappropriately high. This placebo-controlled, randomized, double-blind multicenter study evaluated the efficacy and safety of oral conivaptan, a V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia... CONCLUSION:: Oral conivaptan was effective in increasing serum [Na] in patients with euvolemic or hypervolemic hyponatremia and had a favorable safety profile.
Intravenous conivaptan. 
*Conivaptan is an arginine vasopressin V1A and V2 receptor antagonist...
Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers. [2007.03]
Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure...
Clinical Trials Related to Vaprisol (Conivaptan)
Study of the Safety and Efficacy of Conivaptan (Vaprisol�) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury [Completed]
The investigators plan to utilize conivaptan (Vaprisol) to promote isolated water loss, in
combination with normal (physiologic) fluid replacement to maintain a normal blood volume
status, in patients with severe TBI. The goal of this therapy is to raise blood sodium in a
controlled fashion in subjects with severe TBI, and reduce the use of hypertonic saline
infusion. We hypothesize that this therapy will maintain a stable state of high blood
sodium, while decreasing the overall sodium load needed to achieve these goals.
Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion [Withdrawn]
Heart Failure is a growing and challenging public health concern in the United States. Heart
failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin
is a peptide hormone that is intimately involved in salt and water homeostasis. AVP is
released into the circulation in response low blood volume and hypernatraemia. Despite fluid
overload, vasopressin levels are often inappropriately elevated in patients with heart
failure and LV dysfunction. Data suggest that vasopressin may also contribute to the
deleterious circulatory response in patients with heart failure and play a role in the
development and progression of the disease process. In their study, Udelson et al. showed
that vasopressin receptor antagonism with Conivaptan resulted in significant diuresis with
stable hemodynamics in advanced heart failure patients. Currently Intravenous diuretics and
vasodilators are the standard of care in treating patients with acute decompensated heart
failure. We will be studying the renal and diuretic effects of add on therapy with
intravenous Conivaptan in patients receiving intravenous Nesiritide and intravenous
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol�) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia [Suspended]
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of
intravenous conivaptan in pediatric subjects with abnormally low concentration of sodium in
Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure [Not yet recruiting]
The purpose of the study is to compare the effects of conivaptan and diuretics on renal
blood flow and neurohormones.
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function [Completed]
A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and
moderate liver impairment versus subjects with normal liver function